Mar 15, 2022 8:00 am EDT Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
Mar 4, 2022 7:00 am EST Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.
Feb 8, 2022 8:00 am EST Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
Nov 8, 2021 8:00 am EST Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting
Nov 5, 2021 3:25 pm EDT CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
Nov 4, 2021 8:00 am EDT Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
Oct 25, 2021 8:00 am EDT Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA